Protagonist Therapeutics, Inc. (PTGX)

Market Cap	2.71B
Revenue (ttm)	319.12M
Net Income (ttm)	169.95M
Shares Out	58.90M
EPS (ttm)	2.75
PE Ratio	16.73
Forward PE	99.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	376,341
Open	46.80
Previous Close	46.97
Day's Range	45.51 - 47.03
52-Week Range	13.72 - 48.32
Beta	2.17
Analysts	Strong Buy
Price Target	52.83 (+14.95%)
Earnings Date	Oct 31, 2024

About PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an oral...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: PTGX
• Website: https://www.protagonist-inc.com

Financial Performance

In 2023, Protagonist Therapeutics's revenue was $60.00 million, an increase of 125.73% compared to the previous year's $26.58 million. Losses were -$78.96 million, -38.02% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price forecast is $52.83, which is an increase of 14.95% from the latest price.

Price Target

$52.83

(14.95% upside)

Analyst Consensus: Strong Buy